Cargando…
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency of Tregs and effector Tregs was evident at diagnosis, together with increa...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544983/ https://www.ncbi.nlm.nih.gov/pubmed/35802024 http://dx.doi.org/10.1111/bjh.18302 |
_version_ | 1784804719583035392 |
---|---|
author | Harrington, Patrick Dillon, Richard Radia, Deepti McLornan, Donal Woodley, Claire Asirvatham, Susan Raj, Kavita Curto‐Garcia, Natalia Saunders, Jamie Kordasti, Shahram Harrison, Claire de Lavallade, Hugues |
author_facet | Harrington, Patrick Dillon, Richard Radia, Deepti McLornan, Donal Woodley, Claire Asirvatham, Susan Raj, Kavita Curto‐Garcia, Natalia Saunders, Jamie Kordasti, Shahram Harrison, Claire de Lavallade, Hugues |
author_sort | Harrington, Patrick |
collection | PubMed |
description | The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency of Tregs and effector Tregs was evident at diagnosis, together with increased expression of T‐cell exhaustion markers, including in regulatory T cells at diagnosis and in patients with refractory disease. Plasma analysis revealed significantly increased levels of cytokines including tumour necrosis factor (TNF)‐a and interleukin (IL)‐6 at diagnosis, in keeping with a pro‐inflammatory state prior to treatment. We hence demonstrate T‐cell exhaustion and a pro‐inflammatory state at diagnosis in CML, likely secondary to leukaemia‐associated antigenic overload associated with increased disease burden. |
format | Online Article Text |
id | pubmed-9544983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95449832022-10-14 Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype Harrington, Patrick Dillon, Richard Radia, Deepti McLornan, Donal Woodley, Claire Asirvatham, Susan Raj, Kavita Curto‐Garcia, Natalia Saunders, Jamie Kordasti, Shahram Harrison, Claire de Lavallade, Hugues Br J Haematol Haematological Malignancy–Biology The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency of Tregs and effector Tregs was evident at diagnosis, together with increased expression of T‐cell exhaustion markers, including in regulatory T cells at diagnosis and in patients with refractory disease. Plasma analysis revealed significantly increased levels of cytokines including tumour necrosis factor (TNF)‐a and interleukin (IL)‐6 at diagnosis, in keeping with a pro‐inflammatory state prior to treatment. We hence demonstrate T‐cell exhaustion and a pro‐inflammatory state at diagnosis in CML, likely secondary to leukaemia‐associated antigenic overload associated with increased disease burden. John Wiley and Sons Inc. 2022-07-08 2022-09 /pmc/articles/PMC9544983/ /pubmed/35802024 http://dx.doi.org/10.1111/bjh.18302 Text en © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Haematological Malignancy–Biology Harrington, Patrick Dillon, Richard Radia, Deepti McLornan, Donal Woodley, Claire Asirvatham, Susan Raj, Kavita Curto‐Garcia, Natalia Saunders, Jamie Kordasti, Shahram Harrison, Claire de Lavallade, Hugues Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype |
title |
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype |
title_full |
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype |
title_fullStr |
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype |
title_full_unstemmed |
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype |
title_short |
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype |
title_sort | chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted t‐cell phenotype |
topic | Haematological Malignancy–Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544983/ https://www.ncbi.nlm.nih.gov/pubmed/35802024 http://dx.doi.org/10.1111/bjh.18302 |
work_keys_str_mv | AT harringtonpatrick chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT dillonrichard chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT radiadeepti chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT mclornandonal chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT woodleyclaire chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT asirvathamsusan chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT rajkavita chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT curtogarcianatalia chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT saundersjamie chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT kordastishahram chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT harrisonclaire chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype AT delavalladehugues chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype |